Get the Stockscreener App
1.51
4.86%
0.07
After Hours:
1.52
0.01
+0.66%
Ocugen Inc stock is traded at $1.51, with a volume of 10.11M.
It is up +4.86% in the last 24 hours and down -18.82% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.44
Open:
$1.5
24h Volume:
10.11M
Relative Volume:
1.21
Market Cap:
$511.16M
Revenue:
$4.41M
Net Income/Loss:
$-67.85M
P/E Ratio:
-6.6873
EPS:
-0.2258
Net Cash Flow:
$-57.15M
1W Performance:
-16.11%
1M Performance:
-18.82%
6M Performance:
+11.03%
1Y Performance:
+119.03%
1-Day Range:
$1.445
$1.52
1-Week Range:
$1.38
$1.90
52-Week Range:
$0.64
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.51 | 511.16M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen’s $115 Million Convertible Lifeline Buys Time, but Pipeline Proof Remains the Prize - AD HOC NEWS
Ocugen stock dips as Q1 losses widen - MSN
Ocugen (OCGN) Is Down 16.8% After $115M Convertible Notes Deal And Wider Q1 Losses Has The Bull Case Changed? - Yahoo! Finance Canada
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen (OCGN) Upgraded to Buy: Here's Why - Yahoo Finance
Ocugen’s Convertible Lifeline Fuels a Three-Pronged Gene Therapy Sprint - AD HOC NEWS
Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN
symbol__ Stock Quote Price and Forecast - CNN
Ocugen (NASDAQ: OCGN) posts larger Q1 2026 loss and raises $115M in convertible notes - Stock Titan
Number of shareholders of Ocugen Inc – LSX:A2PSZH - TradingView
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Raises Capital Through Convertible Senior Notes Offering - TipRanks
Ocugen (NASDAQ: OCGN) sells $115M 2034 convertibles, retires Avenue loan - Stock Titan
Chardan Capital Initiates Ocugen(OCGN.US) With Buy Rating, Announces Target Price $7 - Moomoo
Ocugen’s $115 Million Convertible Lifeline Buys Time, but Investors Want Pipeline Proof - AD HOC NEWS
Ocugen’s $115 Million Convertible Bet Raises the Stakes for a Trio of Gene Therapy Trials - AD HOC NEWS
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook - The Globe and Mail
Full Transcript: Ocugen Q1 2026 Earnings Call - Sahm
Ocugen’s Convertible Debt Deal Funds a Pipeline Push, but Investors Balk at Dilution Risk - AD HOC NEWS
Ocugen Q1 2026 Earnings Call Transcript - MarketBeat
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Prices $115 Million Convertible Senior Notes Offering - Moomoo
Ocugen outlines plan for 3 BLAs by 2028 as it expects cash runway into 2028 - MSN
Ocugen Q1 Earnings Call Highlights - Yahoo Finance
Ocugen stock plunges after gene therapy company announces $115M debt sale - The Business Journals
OCGN cash outlook extends to 2028 as OCU400 and OCU410ST enrollment completes - Traders Union
Ocugen prices $115 million convertible notes offering at 6.75% By Investing.com - Investing.com South Africa
Ocugen reports Q1 results, raises $115M in convertible notes By Investing.com - Investing.com Australia
Ocugen Advances Late-Stage Gene Therapies, Bolsters Cash Runway - TipRanks
Ocugen reports Q1 results, raises $115M in convertible notes - Investing.com UK
Ocugen Provides Business Update with First Quarter 2026 Financial Results - Ocugen, Inc.
Ocugen (NASDAQ: OCGN) prices $115M 2034 convertible notes deal - Stock Titan
Ocugen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.
Ocugen Down Over 19%, on Pace for Largest Percent Decrease Since February 2024 -- Data Talk - Moomoo
Earnings call transcript: Ocugen Q1 2026 misses EPS, beats revenue By Investing.com - Investing.com Nigeria
Earnings call transcript: Ocugen Q1 2026 misses EPS, beats revenue - Investing.com
Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Ocugen stock tumbles 17% after convertible notes offering - Investing.com
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 - ChartMill
Ocugen, Inc. announces pricing of $115 million of 6.75% convertible senior notes - marketscreener.com
OCUGEN ($OCGN) Releases Q1 2026 Earnings - Quiver Quantitative
Ocugen: Q1 Earnings Snapshot - Barchart.com
OCGN: Strong clinical progress and extended cash runway position the pipeline for key regulatory milestones - TradingView
Ocugen says two blindness gene therapy trials are fully enrolled - Stock Titan
Ocugen prices $115 million convertible notes offering at 6.75% - Investing.com
Ocugen, Inc. Announces Pricing Of $115 Million Of 6.75% Convertible Senior Notes - TradingView
Q1 2026 Ocugen Inc Earnings Call Transcript - GuruFocus
Ocugen, Inc. Announces Pricing of $115 Million Convertible Senior Notes Offering - Quiver Quantitative
Ocugen's $115M note deal sends $32.7M to repay Avenue loan - Stock Titan
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):